MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

Listen to experts in conversation

Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca

Medical experts come together to share their views in this on-demand webinar replay of an interactive online discussion:

New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

The independent expert panel discussed oral SERDs efficacy and safety profiles in patients with ER+/HER2- advanced or metastatic breast cancer and their place in the treatment landscape
They also covered how to optimise treatment selection and sequencing in ER+/HER2- advanced or metastatic breast cancer and why, when and how to test for ESR1 mutation
The event concluded with speakers and participants engaging in a Q&A to address pressing questions

Watch the replay, broken down into 4 digestible videos, download the accompanying slides, and take the accredited e-learning using the blue button below the videos.

Dr Sara Tolaney

Medical Oncology

Dana-Farber Cancer Institute/Harvard Medical School

United States (US)

Dr Aditya Bardia

Medical Oncologist

Harvard Medical School

United States (US)

Prof. Frédérique Penault-Llorca

Pathologist

University of Clermont-Ferrand

France

Biography Disclosures

Dr Sara Tolaney

Medical Oncology

Dana-Farber Cancer Institute/Harvard Medical School

United States (US)

Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Dr Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She currently chairs several registration studies in these areas and also leads many investigator-initiated trials. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.

Dr Sara Tolaney has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting or Advisory Role: Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Menarini/Stemline, Aadi Biopharma, Bayer

Research Funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Gilead, Seattle Genetics, OncoPep

Biography Disclosures

Dr Aditya Bardia

Medical Oncologist

Harvard Medical School

United States (US)

Dr Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital (MGH), Associate Professor, Harvard Medical School, Boston. As the Director of Breast Cancer Research Program at MGH, Dr Bardia is interested in advancing research to improve the outcomes with breast cancer. Dr Bardia has led the clinical development of antibody drug conjugate (ADC), sacituzumab govitecan, the first ADC approved for patients with metastatic triple negative breast cancer. Dr Bardia has received several research awards including outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, and Douglas Family Foundation prize for excellence in oncology research at MGH. Dr Bardia is the editor of precision medicine clinic section of The Oncologist, co-leader of the Molecular and Precision (MAP) tumor board at MGH, and editorial board member of ASCO molecular oncology tumor board.

Dr Aditya Bardia has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consultant/Advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Eli Lilly, Mersana. Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca, Eli Lilly.

Biography Disclosures

Prof. Frédérique Penault-Llorca

Pathologist

University of Clermont-Ferrand

France

Frédérique PENAULT-LLORCA, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Université d’Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Professor PENAULT-LLORCA is currently professor of Pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin, Clermont-Ferrand, France, and Vice-President of UNICANCER GROUP. She chairs the Immuno- Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies (ESMO, ASCO, ECP, AIP, SFP. Her main areas of interest as a pathology being female cancers. Professor PENAULT-LLORCA has conducted various biomarkers-based research studies in breast, ovarian, colorectal, gastric, and lung cancer in relation to response to targeted therapies and immunotherapies. She also acts as a coordinating pathologist for various oncology trials. Professor PENAULT-LLORCA has written more than 440 peer-reviewed publications and several books on female cancers and biomarker testing methods and issues.

Prof. Frédérique Penault-Llorca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer and Roche.

Overview of Clinical Data of SERDs & Their Place in Treatment Landscape

time Video | open 18 min |accreditation: EACCME | Jul 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download Slides - PDF

Download Slides - PPT

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Advanced or Metastatic Breast Cancer

time Video | open 14 min |accreditation: EACCME | Jul 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

ESR1 Mutation: The Need for & Role of Testing in ER+/HER2- Advanced or Metastatic Breast Cancer

time Video | open 20 min |accreditation: EACCME | Jul 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Panel Discussion and Summary

time Video | open 19 min |accreditation: EACCME | Jul 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Clinical Takeaways

Elacestrant is the 1^st oral SERD to be FDA approved (January 2023) for postmenopausal women or adult men with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer

- FDA approved Guardant360 CDx assay as a companion diagnostic device to identify patients with ER+/HER2- advanced or metastatic breast cancer for treatment with elacestrant
With the aim of redefining treatment landscapes for ER+/HER2- advanced and metastatic breast cancer, several oral SERDs are in clinical development both as monotherapy and in combination therapy with other targeted therapies, including CDK4/6i
ESR1, PI3K, CDK4/6, BRCA, and AKT pathways alterations can be used as targets to guide treatment selection and sequencing decisions in ER+/HER2- advanced or metastatic breast cancer
ESR1 mutational status can be determined without repeated tissue biopsy of a metastatic site; instead, it can be done reliably by liquid biopsy at recurrence or progression on ET

This programme is endorsed by:

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and ECMEC® is available. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

This educational programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology

Other programmes of interest

Prof. Dimitrios Tsakiris

Dr Lars Asmis

Podcast

2 min

Cancer and Thrombosis

Sep 2023

Dr Elisa Agostinetto

Prof. Valentina Guarneri

Interactive patient case

15 min

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Meta...

Sep 2023

Prof. Chee-Kiat Tan

Publication

5 min

Surveillance and Diagnosis of HCC in Asia: Poster Presentation at...

Sep 2023

Assoc. Prof. Gerald Prager

Video

4 min

Long-term Response in Advanced Colorectal Cancer

Sep 2023

Prof. Dr Jeroen Dekervel

Dr Amit Singal

Podcast

29 min

A New Era in Treating Patients with Advanced HCC

Sep 2023

Dr Jaume Capdevila

Asst. Prof. Mauro Cives

Micro learning

30 min

Accreditation: EACCME

Recognising, Diagnosing and Managing Neuroendocrine Tumours

Aug 2023

Acromegaly and Neuroendocrine Tumours Global Survey

Publication

15 min

Acromegaly and Neuroendocrine Tumours Global Survey

Aug 2023

Prof. Shaheenah Dawood

Assoc. Clinical Professor Rena Callahan

Podcast

74 min

Oral SERDs in ER+ Breast Cancer

Aug 2023

Dr Tracy L Stockley

Prof. David Hong

Podcast

24 min

An Introduction to Molecular Testing

Jul 2023

Dr Neal Shore

Dr Andrew J. Armstrong

Video

10 min

Clinical Implementation of Testing and PARPi as Monotherapy or in...

Aug 2023

Janet Forgenie

Video

3 min

Nursing Support for mCRPC Patients During Radiopharmaceutical Tre...

Jul 2023

Prof. Andrea Sartore-Bianchi

Video

5 min

Conference Update: ASCO and WCGIC 2023

Jul 2023

Other programmes developed by Prof. Frédérique Penault-Llorca

Prof. Frédérique Penault-Llorca

Pathologist

University of Clermont-Ferrand

France

Prof. Ezra Cohen

Prof. Frédérique Penault-Llorca

Prof. Silvia Stacchiotti

And others...

30 min

TRK fusion-positive cancer: new ESMO OncologyPRO learning resourc...

Sep 2022

Prof. Frédérique Penault-Llorca

5 min

Using immunohistochemistry to detect TRK fusion-positive cancer

May 2022

Prof. Frédérique Penault-Llorca

Prof. Andrea Sartore-Bianchi

Podcast

20 min

Podcast: TRK fusion-positive GI cancers

Oct 2021

Prof. David Hong

Prof. Ezra Cohen

Prof. Frédérique Penault-Llorca

5 min

Accreditation: EACCME

Current opinions on how to identify and treat NTRK fusion positiv...

Jan 2021

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.